Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dificid approval promises CDAD market shake-up

This article was originally published in Scrip

Executive Summary

On 27 May, the US Food and Drug Administration (FDA) approved San Diego-based Optimer Pharmaceuticals' Dificid (fidaxomicin), a new antibiotic for the treatment of Clostridium difficile-associated diarrhoea (CDAD).

You may also be interested in...

End of an era in antibiotic blockbusters as FDA approves Levaquin generics

The US Food and Drug Administration has approved the first generic versions of Johnson & Johnson’s blockbuster antibacterial drug Levaquin (levofloxacin). Twelve companies, including generic heavyweights Mylan and Teva Pharmaceutical Industries, had applied to market generic versions of the drug in the lucrative US market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts